Good and bad news for Cambridge kits
This article was originally published in Clinica
The US Bankruptcy Court has upheld Cambridge Biotech's licence under two patents issued to the Institut Pasteur for HIV-2 tests. However, it also ruled that Cambridge Biotech's HIV-1 Western blot confirmatory test infringes a third patent issued to the Institut Pasteur and so prevents the company from manufacturing and selling it. The latter test accounted for less than 15% of the company's diagnostic revenue in 1994, says Cambridge, which says it will appeal the decision.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.